Trial Profile
A retrospective study evaluating EGFR Amplification and Sensitizing Mutations Correlate with Survival in Lung Adenocarcinoma Patients Treated with Erlotinib
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 15 Oct 2018
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary)
- Indications Adenocarcinoma; Lung cancer; Non-small cell lung cancer
- Focus Pharmacodynamics; Therapeutic Use
- 15 Oct 2018 New trial record
- 04 Oct 2018 Results published in the Targeted Oncology